$YCBD

cbdMD, Inc.

Insider trades
1
0
0

No SEC Form 4 filings for $YCBD in the last 30 days.

See all $YCBD insider activity →
Med

cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

cbdMD, Inc. (NYSE American: YCBD) reported Q3 FY2026 results ended June 30, 2026. Revenue rose 20% year over year to $5.6 million, driven by 61% higher wholesale net sales and a full quarter contribution from Bluebird Botanicals. Oasis distribution expanded. Loss from operations was about $1.13 million. The company cited federal hemp legislation timing and expected monthly cost savings up to $150,000.

cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products

cbdMD, Inc. (NYSE American: YCBD) said a Senate continuing resolution released Aug. 2 would delay federal hemp restrictions on most hemp products from Nov. 12 to Dec. 11, preserving access to naturally derived full-spectrum CBD. The company said the language is not yet law and would need final House and Senate approval and presidential signature.

YCBD sentiment & insider activity

Over the past 7 days, alphai's AI scored 1 news story mentioning YCBD (cbdMD, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent YCBD coverage spans financial news, regulation and earnings.

What's driving YCBD

  • Results and regulatory commentary suggest improving top-line momentum, but margins and operating losses remain pressured by integration and compliance costs.

    prnewswire.com · Aug 13, 2026

  • The proposed delay reduces near-term regulatory overhang for cbdMD’s naturally derived, full-spectrum CBD portfolio, but it is not yet law.

    prnewswire.com · Aug 3, 2026

  • The company is positioning for a regulatory outcome that would preserve full-spectrum CBD access and prevent lawful products from being removed from the market.

    prnewswire.com · Jul 24, 2026

  • The partnership is a brand-marketing and CSR initiative with limited direct financial disclosure, so near-term fundamentals likely move modestly at most.

    prnewswire.com · Jul 9, 2026

  • Management optimism following March-quarter results is discussed, but the piece does not provide new, concrete financial datapoints or guidance changes.

    insidermonkey.com · May 31, 2026

alphai scores every news story that mentions YCBD with an AI model for sentiment and relevance, and aggregates insider trades from cbdMD, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $YCBD

Score

cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

cbdMD, Inc. (NYSE American: YCBD) reported Q3 FY2026 results ended June 30, 2026. Revenue rose 20% year over year to $5.6 million, driven by 61% higher wholesale net sales and a full quarter contribution from Bluebird Botanicals. Oasis distribution expanded. Loss from operations was about $1.13 million. The company cited federal hemp legislation timing and expected monthly cost savings up to $150,000.

cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products

cbdMD, Inc. (NYSE American: YCBD) said a Senate continuing resolution released Aug. 2 would delay federal hemp restrictions on most hemp products from Nov. 12 to Dec. 11, preserving access to naturally derived full-spectrum CBD. The company said the language is not yet law and would need final House and Senate approval and presidential signature.

cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access

cbdMD, Inc. (NYSE American: YCBD) said it supports the bipartisan Lawful Hemp Protection Act by Reps. Andy Barr and Angie Craig, which would set a long-term federal regulatory framework for hemp-derived products. The company also backed an administration call to update the federal hemp definition before a Nov. 12, 2026 narrowing deadline under FY2026 appropriations.

cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation

cbdMD, Inc. (NYSE American: YCBD) said its Bluebird Botanicals brand partnered with Denver Audubon to support bird conservation in Colorado. Under the “Buy Bluebird, Save Bluebirds” campaign, Bluebird will contribute 1% of profits from Bluebird product sales over three months this summer. cbdMD said the move follows its investment in Bluebird after acquiring the brand.

$YCBDMed

Lease change at cbdMD (NYSE: YCBD) cuts annual rent and shrinks footprint

cbdMD has extended and restructured the lease for its Charlotte, North Carolina headquarters and warehouse facilities, securing a new expiration date of November 30, 2031. The company will reduce its leased footprint to 40,000 square feet, which management believes is sufficient for current and future operations. This amendment is expected to result in an annual gross rent expense reduction of approximately $450,000 and a net rent expense reduction of $100,000 to $120,000 after accounting for sublet income.

$YCBDMed

cbdMD Q2 2026 Deep Dive: EPS Misses by 60.0%, Revenue Up 19%

cbdMD (YCBD) reported mixed Q2 2026 results, with EPS missing estimates by 60.0% at -$0.08, despite revenue of $5.6M beating expectations by 6.6% and growing 19% year-over-year. The company faces profitability challenges, evidenced by a deteriorating net margin of -14.2% and increased reliance on lower-margin wholesale channels, as well as organic growth concerns for its core CBD business. Investors will be watching for signs of operating leverage, stabilization of the DTC channel, and management of cash burn.

$YCBDMed

cbdMD Q2 2026 Loss Deepens: -$0.08/Share vs -$0.05 Expected

cbdMD (YCBD) reported a mixed Q2 2026, with revenue exceeding expectations but a wider-than-anticipated loss per share. The company posted a loss of $0.08 per share against an estimated $0.05 loss, while revenue hit $5.6M, beating the $5.3M estimate. Despite the quarterly loss, cbdMD showed significant year-over-year improvement, with EPS narrowing by 95.8% and revenue growing by 19.0%.

cbdMD raises $2.25 million through preferred stock offering By Investing.com

cbdMD, Inc. has successfully raised $2.25 million through the issuance of Series C Convertible Preferred Stock to institutional investors. The company plans to use the net proceeds, approximately $2.1 million, for working capital, general corporate purposes, and to support strategic initiatives aimed at expanding distribution and achieving sustained profitability. This move follows other recent financial and operational developments, including regaining compliance with NYSE American standards and entering a new executive employment agreement.

Related tickers